Psilocybin for Addiction: What the Clinical Trials Found
Addiction is one of the most treatment-resistant conditions in medicine. Relapse rates for alcohol, tobacco, and opioid addiction remain stubbornly high despite decades of pharmacological and behavioral interventions. Psilocybin has produced some of the most striking results in addiction research — results that have surprised even skeptical researchers.
Tobacco Addiction: The Johns Hopkins Study
A 2014 Johns Hopkins pilot study gave 15 smokers two or three psilocybin sessions (20–30mg) combined with cognitive behavioral therapy for smoking cessation. At 6-month follow-up, 80% of participants had quit smoking — compared to 35% for nicotine replacement therapy and 22% for varenicline (Chantix), the most effective pharmaceutical option. At 12-month follow-up, 67% remained abstinent. These are extraordinary numbers for tobacco cessation.
Alcohol Use Disorder: NYU and UCSF Trials
A 2022 JAMA Psychiatry study randomized 93 adults with alcohol use disorder to receive either two psilocybin sessions or antihistamine (active placebo). The psilocybin group showed significantly greater reductions in heavy drinking days (from 52% to 10% of days) compared to placebo (from 52% to 24%). These effects persisted at 8-month follow-up.
Why Psilocybin Works for Addiction
Addiction involves rigid, compulsive behavioral patterns driven by hyperactivated reward circuits and impaired prefrontal control. Psilocybin disrupts these patterns through neuroplasticity — creating a window during which new, non-addictive patterns can form. The "mystical experience" quality of psilocybin sessions also appears to produce profound shifts in values and self-concept that support sustained behavior change.